Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
UroGen Pharma Ltd(URGN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for URGN
11/13/2026: URGN (4-star) is currently NOT-A-BUY. Pass it for now.
UroGen Pharma is a commercial-stage biotechnology company that provides specialized, localized therapies for urothelial and urological cancers. The company’s main strength is its proprietary hydrogel-based delivery technology, which has enabled the first approved non-surgical treatment for upper tract urothelial cancer. Its primary growth opportunity lies in the potential approval and commercialization of its pipeline candidate, UGN-102, for bladder cancer. However, the company faces significant risks, including clinical development volatility, competition from entrenched surgical standards, and the need for ongoing capital. This stock may suit growth-oriented investors who can tolerate high clinical risk and volatility while monitoring the company's progress in expanding its product portfolio.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | The company is in an active growth phase with potential for major catalysts like new product approvals. |
| Momentum investor | Mixed fit | This style is conditional on positive clinical outcomes and upward price trends following key data releases. |
| Value investor | Weak fit | The company is not currently valued based on traditional earnings or P/E multiples due to its growth-stage nature. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on reinvestment. |
| Low-risk investor | Weak fit | The high volatility and clinical trial risk make this unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to binary clinical trial results and regulatory decisions. |
| Valuation risk | Medium / high | Valuations are based on future potential rather than current cash flows, creating downside risk if expectations are not met. |
| Competition risk (Surgical/Oncology standards) | Medium | Competing against established surgical practices is difficult and requires significant behavioral change among physicians. |
| Business quality | Medium | The reliance on a single approved product makes the business model fragile until a broader portfolio is established. |
| Dividend income | Low / none | This is a non-dividend-paying biotech company. |
| Execution risk | High | Successfully scaling commercial operations while managing late-stage clinical development is inherently challenging. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.26B USD | Price to earnings Ratio - | 1Y Target Price 60.71 |
Price to earnings Ratio - | 1Y Target Price 60.71 | ||
Volume (30-day avg) 1.3M shares | Beta 1.64 | 52 Weeks Range 16.50 - 50.81 | Updated Date 11/13/2026 |
52 Weeks Range 16.50 - 50.81 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.31 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 68.13% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue generated from the commercial sale of Jelmyto. | The company makes money by selling a specialized drug that treats cancer without requiring surgery. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When Before Market | Estimate 0.05 | Actual -0.03 |
Profitability
Profit Margin -26.27% | Operating Margin (TTM) -12.36% |
Management Effectiveness
Return on Assets (TTM) -8.46% | Return on Equity (TTM) -1481.26% |
Valuation
Trailing PE - | Forward PE 12.94 | Enterprise Value 1.40B | Price to Sales(TTM) 5.02 |
Enterprise Value 1.40B | Price to Sales(TTM) 5.02 | ||
Enterprise Value to Revenue 5.59 | Enterprise Value to EBITDA -2.63 | Shares Outstanding 49.05M | Shares Floating 43.58M |
Shares Outstanding 49.05M | Shares Floating 43.58M | ||
Percent Insiders 3.48 | Percent Institutions 99.39 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.